Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Pinho-Schwermann

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Biorxiv : the Preprint Server for Biology|September 11, 2024
Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell LinesConnor Purcell, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
American Journal of Translational Research|January 17, 2025
Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell linesConnor Purcell, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
Cancers|February 13, 2025
Heterogeneity in CancerWilliam J MacDonald, Connor Purcell, Maximilian Pinho-Schwermann, et al.
American Journal of Cancer Research|October 17, 2024
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationVida Tajiknia, Maximilian Pinho-Schwermann, Praveen R Srinivasan, et al.
American Journal of Cancer Research|January 12, 2026
Inhibition of ITGB6 stimulates potent anti-tumor responses in immunocompetent mouse models of head and neck squamous cell carcinoma and pancreatic adenocarcinomaWilliam J MacDonald, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
American Journal of Cancer Research|January 13, 2025
Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancerLaura Jinxuan Wu, Maximilian Pinho-Schwermann, Lanlan Zhou, et al.
Transplantation Proceedings|November 1, 2019
Liver Transplantation for Non-hepatocellular Carcinoma Malignancy: A Single-Center ExperienceAlessandra Maria Mont Alverne Pierre, Camila Monteiro Veras, Ticiana Mota Esmeraldo, et al.
Journal of Clinical Medicine|November 3, 2018
Angiopoietin-2: A Potential Mediator of the Glycocalyx Injury in Adult Nephrotic PatientsMaria Moura Santana Chaves, Matheus de Souza Mendes, Maximilian Pinho Schwermann, et al.
Cancer Treatment Reviews|December 2, 2025
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancerClaire Lin, Matthew J Hadfield, Amol Rathore, et al.
The Journal of Clinical Investigation|July 15, 2025
Corrigendum to Targeting apoptotic pathways for cancer therapyXiaobing Tian, Praveen R Srinivasan, Vida Tajiknia, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biorxiv : the Preprint Server for Biology|September 11, 2024
Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell LinesConnor Purcell, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
American Journal of Translational Research|January 17, 2025
Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell linesConnor Purcell, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
Cancers|February 13, 2025
Heterogeneity in CancerWilliam J MacDonald, Connor Purcell, Maximilian Pinho-Schwermann, et al.
American Journal of Cancer Research|October 17, 2024
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationVida Tajiknia, Maximilian Pinho-Schwermann, Praveen R Srinivasan, et al.
American Journal of Cancer Research|January 12, 2026
Inhibition of ITGB6 stimulates potent anti-tumor responses in immunocompetent mouse models of head and neck squamous cell carcinoma and pancreatic adenocarcinomaWilliam J MacDonald, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
American Journal of Cancer Research|January 13, 2025
Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancerLaura Jinxuan Wu, Maximilian Pinho-Schwermann, Lanlan Zhou, et al.
Transplantation Proceedings|November 1, 2019
Liver Transplantation for Non-hepatocellular Carcinoma Malignancy: A Single-Center ExperienceAlessandra Maria Mont Alverne Pierre, Camila Monteiro Veras, Ticiana Mota Esmeraldo, et al.
Journal of Clinical Medicine|November 3, 2018
Angiopoietin-2: A Potential Mediator of the Glycocalyx Injury in Adult Nephrotic PatientsMaria Moura Santana Chaves, Matheus de Souza Mendes, Maximilian Pinho Schwermann, et al.
Cancer Treatment Reviews|December 2, 2025
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancerClaire Lin, Matthew J Hadfield, Amol Rathore, et al.
The Journal of Clinical Investigation|July 15, 2025
Corrigendum to Targeting apoptotic pathways for cancer therapyXiaobing Tian, Praveen R Srinivasan, Vida Tajiknia, et al.
Pageof 2